
Sino-Agri Leading Biosciences Co.,Ltd
SSE:603970.SS
12.95 (CNY) • At close April 30, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue
| 10,595.818 | 10,459.621 | 11,698.775 | 8,822.111 | 6,640.994 | 4,342.465 | 3,734.627 | 3,503.462 | 3,398.425 | 3,234.19 | 2,875.108 | 2,488.048 | 2,144.799 |
Cost of Revenue
| 9,847.479 | 9,688.228 | 10,931.127 | 8,268.855 | 6,107.243 | 3,896.772 | 3,317.577 | 3,084.533 | 2,994.863 | 2,836.779 | 2,517.338 | 2,199.957 | 1,929.866 |
Gross Profit
| 748.339 | 771.394 | 767.648 | 553.257 | 533.751 | 445.694 | 417.05 | 418.929 | 403.562 | 397.411 | 357.77 | 288.091 | 214.933 |
Gross Profit Ratio
| 0.071 | 0.074 | 0.066 | 0.063 | 0.08 | 0.103 | 0.112 | 0.12 | 0.119 | 0.123 | 0.124 | 0.116 | 0.1 |
Reseach & Development Expenses
| 67.837 | 66.557 | 46.853 | 38.955 | 35.276 | 31.826 | 13.146 | 2.149 | 1.068 | 1.182 | 2.32 | 1.738 | 1.375 |
General & Administrative Expenses
| 24.02 | 17.768 | 11.731 | 13.867 | 14.46 | 11.648 | 10.581 | 15.139 | 15.703 | 16.301 | 13.525 | 42.928 | 31.017 |
Selling & Marketing Expenses
| 126.584 | 243.68 | 223.601 | 181.313 | 171.369 | 165.647 | 181.636 | 210.951 | 216.102 | 207.327 | 176.836 | 151.243 | 102.554 |
SG&A
| 150.604 | 261.448 | 235.331 | 195.18 | 185.829 | 177.295 | 192.217 | 226.089 | 231.805 | 223.628 | 190.361 | 194.171 | 133.571 |
Other Expenses
| 228.425 | 127.983 | 50.272 | 50.859 | 46.573 | 46.172 | 1.052 | 0.711 | 42.61 | 47.3 | 40.356 | 38.233 | 8.344 |
Operating Expenses
| 446.866 | 455.988 | 332.457 | 284.994 | 267.679 | 255.293 | 243.045 | 265.097 | 266.614 | 260.232 | 220.744 | 194.412 | 134.051 |
Operating Income
| 301.473 | 315.406 | 324.894 | 345.736 | 211.421 | 209.024 | 156.942 | 122.72 | 74.968 | 75.492 | 79.417 | 59.25 | 69.608 |
Operating Income Ratio
| 0.028 | 0.03 | 0.028 | 0.039 | 0.032 | 0.048 | 0.042 | 0.035 | 0.022 | 0.023 | 0.028 | 0.024 | 0.032 |
Total Other Income Expenses Net
| 0.634 | -0.28 | 0.796 | -105.497 | -3.961 | -53.39 | 1.052 | 1.019 | 42.054 | 47.296 | 40.354 | 38.187 | 8.335 |
Income Before Tax
| 302.108 | 315.126 | 325.69 | 240.239 | 207.46 | 155.634 | 157.993 | 123.739 | 117.445 | 122.789 | 119.772 | 97.437 | 77.943 |
Income Before Tax Ratio
| 0.029 | 0.03 | 0.028 | 0.027 | 0.031 | 0.036 | 0.042 | 0.035 | 0.035 | 0.038 | 0.042 | 0.039 | 0.036 |
Income Tax Expense
| 73.233 | 67.548 | 77.781 | 54.604 | 52.409 | 31.145 | 42.843 | 34.046 | 33.129 | 39.185 | 34.325 | 25.994 | 20.799 |
Net Income
| 203.377 | 224.841 | 210.315 | 170.309 | 132.444 | 118.876 | 115.459 | 90.33 | 81.717 | 88.267 | 80.719 | 68.724 | 55.462 |
Net Income Ratio
| 0.019 | 0.021 | 0.018 | 0.019 | 0.02 | 0.027 | 0.031 | 0.026 | 0.024 | 0.027 | 0.028 | 0.028 | 0.026 |
EPS
| 0.76 | 0.84 | 0.78 | 0.63 | 0.49 | 0.44 | 0.43 | 0.44 | 0.41 | 0.44 | 0.4 | 0.39 | 0.34 |
EPS Diluted
| 0.76 | 0.84 | 0.78 | 0.63 | 0.49 | 0.44 | 0.43 | 0.44 | 0.41 | 0.44 | 0.4 | 0.39 | 0.34 |
EBITDA
| 357.508 | 352.805 | 375.851 | 299.821 | 262.228 | 214.628 | 196.93 | 160.799 | 201.832 | 190.199 | 167.491 | 97.465 | 82.681 |
EBITDA Ratio
| 0.034 | 0.034 | 0.032 | 0.034 | 0.039 | 0.049 | 0.053 | 0.046 | 0.059 | 0.059 | 0.058 | 0.039 | 0.039 |